Consistent with this notion, the combination of BET bromodomain inhibitor JQ1 and TKIs has been suggested to be a rational strategy for treating leukemia and lymphoma.42 Additionally, BRD2 was shown to positively control epithelial‐mesenchymal transition in breast cancer,43 and a GS for this histologic transformation could forecast the resistance to EGFR inhibitor erlotinib in both wild‐type EGFR and mutant EGFR lung cancer cases.44 Here, BRD2 is linked to breast cancer.